XML 35 R23.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segment and Related Information | 3 Months Ended
--- | ---
Sep. 30, 2018
Segment Reporting [Abstract] |
Segment and Related Information |
(16) | SEGMENT AND RELATED INFORMATION
The Company’s business is aligned with how the Chief Operating Decision Maker reviews performance and makes decisions in managing the Company. The business units have been aggregated into two reportable segments: (i) diagnostics and (ii) other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology. Segment revenue and operating income (loss) were as follows during the periods presented:
|  | Diagnostics |  |  | Other |  |  | Total |
Three months ended September 30, 2018 |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  | $ | 189.0 |  |  | $ | 13.3 |  |  | $ | 202.3 |
Depreciation and amortization |  |  | 17.0 |  |  |  | 1.3 |  |  |  | 18.3 |
Segment operating income (loss) |  |  | 27.6 |  |  |  | (26.4 | ) |  |  | 1.2 |
Three months ended September 30, 2017 |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  | $ | 167.4 |  |  | $ | 11.4 |  |  | $ | 178.8 |
Depreciation and amortization |  |  | 11.8 |  |  |  | 1.4 |  |  |  | 13.2 |
Segment operating income |  |  | 30.6 |  |  |  | 53.4 |  |  |  | 84.0 |
|  | Three months ended |
|  | September 30, |
|  | 2018 |  |  | 2017 |
Total operating income for reportable segments |  | $ | 1.2 |  |  | $ | 84.0 |
Unallocated amounts: |  |  |  |  |  |  |  |
Interest income |  |  | 0.7 |  |  |  | 0.4 |
Interest expense |  |  | (2.2 | ) |  |  | (0.9 | )
Other |  |  | 1.1 |  |  |  | (0.3 | )
Income from operations before income taxes |  |  | 0.8 |  |  |  | 83.2 |
Income tax provision |  |  | 1.6 |  |  |  | 4.5 |
Net income (loss) |  |  | (0.8 | ) |  |  | 78.7 |
Net loss attributable to non-controlling interest |  |  | (0.1 | ) |  |  | (0.1 | )
Net income (loss) attributable to Myriad Genetics, Inc. stockholders |  | $ | (0.7 | ) |  | $ | 78.8 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration